Connect with us

Government

Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist

Which biotech stocks are you watching today?
The post Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Published

on

Here Are 5 Biotech Stocks To Check Out In The Stock Market Today

As we move into the rest of 2022, it seems that biotech stocks could continue to be a viable play in the stock market. This can be attributed to the ongoing coronavirus concerns fueling the booming industry. Now, as the Omicron variant sweeps the globe, it shouldn’t come as a surprise as many investors continue to look out for the best biotech stocks to buy. Despite daily new cases seeming to be slowing down in the U.S, the persistent uncertainty has weighed on investors’ expectations regarding the overall market. Also, with rising interest rates hampering tech stocks, the biotech segment does seem appealing these days, given its non-cyclical nature.

All in all, some of the prominent names in the industry today would still center around vaccine makers. Just last week, it was found that a Johnson & Johnson (NYSE: JNJ) booster shot is 85% effective in protecting against hospitalization by the Omicron variant. In other vaccine-related news, Moderna (NASDAQ: MRNA) CEO Stephane Bancel recently provided an update on the company’s work with the Omicron variant. The CEO notes that clinical data for Moderna’s vaccine candidate could arrive by March. While these vaccine stocks remain topics of discussion, other players in the biotech space could be worth mentioning as well. In light of all these, do you have this list of top biotech stocks to watch in the stock market now?

Top Biotech Stocks To Watch In January 2022

Zogenix

Shares of small-cap biotech stock Zogenix have been moving higher this week. This was thanks to the breaking news on Wednesday regarding an acquisition. In detail, the company’s shares are responding positively to a buyout agreement from Belgian pharmaceutical company UCB. Under the agreement, UCB will be buying all outstanding Zogenix shares for $26.00 per share. Besides that, there is also a milestone-based potential cash payment of $2.00 per share. 

zgnx stock

For those who come across the company for the first time, it is a biopharmaceutical company that develops therapies to improve the lives of patients with rare diseases. The company’s first rare disease therapy, FINTEPLA (fenfluramine) oral solution, has been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

Besides the two healthcare authorities, fenfluramine is also under regulatory review in Japan. Fenfluramine treats seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. Given all this and the recent buyout deal, will you be watching ZGNX stock?

[Read More] Top Stocks To Buy Now? 4 Renewable Energy Stocks For Your Watchlist

Valneva

Following that, we have Valneva. In brief, it is a French biotech that develops prophylactic vaccines for infectious diseases. As a matter of fact, it currently has several vaccines in development, including vaccines against Lyme disease, coronavirus, and chikungunya. Valneva’s portfolio also includes two commercial vaccines for travelers. 

VALN stock chart

On Wednesday, the company said that preliminary studies showed that three doses of its inactivated COVID-19 vaccine candidate VLA2001 neutralized the Omicron variant of the disease. All of the serum samples tested presented neutralizing antibodies against the ancestral virus and Delta variant, and 87% against the Omicron variant. The company expects to receive potential approvals for its vaccine within the first three months of this year.

Besides that, it will also be providing data to the EMA as well as regulators in the UK and Bahrain. If Europe approves the shot, Valneva expects to start delivering doses there in April. With this potentially groundbreaking development in mind, should you buy VALN stock?

[Read More] Best Lithium Battery Stocks To Buy Now? 4 To Know

Pfizer 

Without a doubt, Pfizer is one of the most notable names in the COVID-19 vaccine arena. The biopharmaceutical develops and manufactures many health care products that include innovative medicines and vaccines.

biotech stocks to buy (PFE stock)

The company is also behind many blockbuster drugs, drugs that have brought in a revenue of over $1 billion. Most notably, its COVID-19 vaccine was developed together with BioNTech (NASDAQ: BNTX). Over the past 6 months, Pfizer stock has risen by over 30%.

Yesterday, White House Chief Medical Advisor Dr Anthony Fauci said that the FDA could approve its vaccine for children under 5 years old by next month. He also notes that younger children will likely need three doses, as two shots did not induce an adequate immune response in 2-4-year-olds in Pfizer’s clinical trials. “My hope is that it’s going to be within the next month or so and not much later than that, but I can’t guarantee that,” Fauci said during an interview. With Pfizer continuing to lead the fight against the pandemic, will you be watching PFE stock?

Novavax

Following that, we have Novavax. In short, the company develops vaccines to counter serious infectious diseases. Its recombinant nanoparticles and adjuvant technology continue to be the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. 

best biotech stocks (NVAX stock)

Novavax announced yesterday that Australia’s Therapeutic Goods Administration (TGA) has finally granted approval for the company’s COVID-19 vaccine for active immunization in individuals 18-years-old and older. In January 2021, the country entered into an advance purchase agreement to order 51 million doses of the vaccine for its population of 26 million.

Moreover, Australia has the option to purchase an additional 10 million doses as well. Supplied under the brand Nuvaxovid, this approval represents the first protein-based COVID-19 vaccine to be used in Australia. Given this piece of news, is NVAX stock one to watch?

[Read More] Best Monthly Dividend Stocks To Buy Now? 5 For Your List

AbbVie

Leading biopharmaceutical company AbbVie focuses on developing treatments across a wide array of therapeutics areas. Among the core areas of AbbVie’s focus are immunology, neuroscience, eye care, oncology, and gastroenterology.

best dividend stocks (ABBV stock)

Additionally, the company also offers aesthetics-based treatments via its Allergan Aesthetics portfolio. For a sense of scale, the company raked in a total revenue of $14.34 billion in its latest quarter. ABBV stock has risen by over 15% in price over the past 6 months.

Last week, the FDA approved the company’s Rinvoq (upadacitinib) for the treatment of moderate to severe atopic dermatitis. The treatment is for adults and adolescents 12-years-old and older whose disease did not respond to previous treatment options or when other options are not advised. AbbVie has eyed the drug as a potential successor to its blockbuster drug Humira, which has been the primary driver of revenue for the company. Given this approval and potential cash cow drug, will you be eyeing ABBV stock?


If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!


The post Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Read More

Continue Reading

Government

Sheila Ochugboju named Executive Director of Alliance for Science

Boyce Thompson Institute (BTI) is pleased to welcome Sheila Ochugboju as the new Executive Director of the Alliance for Science (AfS), a global communications…

Published

on

Boyce Thompson Institute (BTI) is pleased to welcome Sheila Ochugboju as the new Executive Director of the Alliance for Science (AfS), a global communications initiative dedicated to promoting access to scientific innovation as a means of enhancing food security, improving environmental sustainability, and raising the quality of life globally. Her start date is June 1.

Credit: Image provided/Sheila Ochugboju

Boyce Thompson Institute (BTI) is pleased to welcome Sheila Ochugboju as the new Executive Director of the Alliance for Science (AfS), a global communications initiative dedicated to promoting access to scientific innovation as a means of enhancing food security, improving environmental sustainability, and raising the quality of life globally. Her start date is June 1.

“We are delighted that Dr. Ochugboju will soon be joining us,” said BTI President David Stern. “The Alliance plays a vital role in connecting a range of stakeholders with up-to-date and vital information about how scientific advances can contribute to the future of the planet’s health, an effort that aligns perfectly with BTI’s mission to advance and communicate scientific discovery in plant biology to improve agriculture, protect the environment, and enhance human health.”

“We are fortunate to have someone with Sheila’s experience, connections and vision in this role,” Stern added.

Ochugboju is a leader in science communication and has been a global advocate for science technology and innovation for more than 20 years. She was most recently the Head of Strategic Communications at the Africa Centres for Disease Control and Prevention (Africa CDC), supporting vaccine delivery communication across Africa and advocating for vaccine equity.

She is also a founding member of the Network of African Women Environmentalists (NAWE), leading in the development of flagship initiatives and products such as the Earth Science Cafes, The Youth Earth Guardians and Landscape Mentors network and the Earth Reflections Podcast, which was rated amongst the leading environment podcasts in Africa in 2020.

“I am excited to join the Boyce Thompson Institute, because together with the Alliance for Science we can offer new lenses, tools, and partnerships to transform how the world understands the role of science in addressing global challenges,” said Ochugboju. “The COVID-19 pandemic, climate change and now food security challenges are teaching everyone that good science communication can literally save lives and livelihoods.”

Founded in 2014, AfS is a global communications initiative that seeks to counter misinformation about agricultural biotechnology, climate change, nuclear power, vaccines, COVID-19 and other contemporary science issues.

To support its work, the Alliance relies on a global network of about 14,000 science allies who engage in their local communities to advance science-based policies. AfS has trained more than 900 science champions, including scientists, farmers, journalists, healthcare professionals and students, in 48 countries to communicate effectively about biotechnology.

“After a comprehensive executive search, we are thrilled to have found someone like Dr. Ochugboju, who has the knowledge and ability to broaden the horizon of the Alliance for Science and bring resources to counter misinformation across a more substantial expanse of scientific endeavor, especially including climate change,” said Ronnie Coffman, Professor of Global Development at Cornell University and Interim Director of AfS.  

Ochugboju graduated with a degree in Medical Biochemistry and then received her Ph.D. in Plant Biochemistry from Royal Holloway, University of London in 1996. She was awarded the Daphne Jackson Trust Post-Doctoral Research Fellowship, based at the Centre for Ecology & Hydrology, St. Hilda’s College, University of Oxford in 1998.

She has lived and worked in Africa, Europe and the Middle East. In 2016, she received a WINGS WorldQuest Women of Discovery Award for developing and leading pioneering African science, technology and innovation projects. Ochugboju was also appointed as a Global Roving Ambassador for the county government of Kisumu, Kenya, in charge of the portfolio for Transformative Science and Urban Resilience.

About Boyce Thompson Institute:

Opened in 1924, Boyce Thompson Institute is a premier life sciences research institution located in Ithaca, New York. BTI scientists conduct investigations into fundamental plant and life sciences research with the goals of increasing food security, improving environmental sustainability in agriculture, and making basic discoveries that will enhance human health. Throughout this work, BTI is committed to inspiring and educating students and to providing advanced training for the next generation of scientists. BTI is an independent nonprofit research institute that is also affiliated with Cornell University. For more information, please visit BTIscience.org.

 

###


Read More

Continue Reading

International

How Crowded Are Royal Caribbean, Carnival Cruise Ships Right Now?

Both cruise lines have raised capacities slowly. When will Royal Caribbean and Carnival hit normal?

Published

on

Both cruise lines have raised capacities slowly. When will Royal Caribbean and Carnival hit normal?

When Freedom of the Seas sailed from Miami on July 2, 2021, it marked Royal Caribbean International's (RCL) - Get Royal Caribbean Group Report return to North American sailing after being shut down since March 2020. 

That sailing has less than 1,000 people on it, mostly loyal cruisers eager to get back to sea no matter what the rules were (as well as a fair amount of company executives.

That ship can hold 4,375 passengers at full capacity, according to Ship Technology and on that July sailing, it felt empty and crew seemed to outnumber passengers. 

At night, in the British Pub, the crowd was essentially me, two other journalists, and the occasional person who wandered by. 

That made it, perhaps, too easy to get a drink, and while it was a wonderful experience, that sailing only felt normal when everyone onboard took to the upper decks to cheer sail away and celebrate the Fourth of July,

I sailed on Freedom on that July sailing, then again in September, October, November, December, and then again in May.

I sailed Odyssey of the Seas and Wonder of the Seas in between January and May. 

The crowds got progressively bigger through the fall, but even the December sailing (a three-day weekend, which in pre-pandemic times would be at or near capacity) still had a limited capacity.

Royal Caribbean steadily increased the number of people on its ships, with some slight pauses in that as new covid variants popped up and Carnival Cruise Lines (CCL) - Get Carnival Corporation Report has followed roughly the same model.   

Dukas/Universal Images Group via Getty Images

Cruise Lines Capacity Is Coming Back

How crowded will my cruise be? 

This has been a question seemingly every experienced cruiser has asked. In the summer and fall, that answer was "not at all," and later "not as much as usual," but the numbers of passengers onboard has slowly moved back to normal, even reaching it on some sailings.

Cruise lines generally don't offer a lot of comment on why they might be limiting capacity when technically they no longer have. 

Crew concerns, including not being able to onboard new crew members to allow for full sailings due to slow visa processing times and keeping rooms open fr potential covid quarantines have kept some ships below their full complement of passengers.

Demand, of course, factors in as well. Royal Caribbean CFO Naftali Holtz commented on where his company stands now during its first-quarter earnings call.

"I'd like to comment on capacity and load factor expectations over the upcoming period. We plan to restart operations on all remaining ships by the end of June. 

"We plan to operate about 10.3 million APCDs [available passenger cruise days] during the second quarter, and we expect load factors of approximately 75% to 80%," he said. 

"Our load factor expectations reflect the higher occupancy we are seeing in the Caribbean and lower expectations for repositioning voyages and early season Europe sailings."

It's clear that demand is a factor when it comes to why certain sailings are sailing with fewer passengers than others. 

Carnival has had to limit the cabins it has been selling on its United Kingdom-based Cunard line due to staffing issues.

“As you may have seen in the news, the wider impact of Covid-19 is affecting hospitality and is disrupting airlines and as such this is impacting the number of crew members we are able to get to our ships,” said the company in a statement.

“We naturally want to ensure that all guests across the fleet experience the high standards of service on board that they would expect from Cunard and which we are committed to delivering,” the company added. 

“We are therefore limiting the number of guests sailing as we build crew numbers back up."

Normal Cruise Crowds Are Coming

Once staffing issues return to normal — something that is slowly happening — the biggest concern may be whether the economy slows demand. 

Carnival CEO Arnold Donald said he expects his company to get close to normal over the summer during the cruise line's first-quarter earnings call.

"We're well on our way back to full cruise operations, with three-quarters of our capacity having resumed guest operations and a plan to return the balance of the fleet for the summer season. And while the conversation around covid-19 is greatly reduced, we still have to and are successfully actively managing," he said.

And while neither Carnival's nor Royal Caribbean's CEO said it directly, passengers sailing this summer will likely experience passenger counts in line with tradition. 

That does not mean some sailings won't have limited capacities, or sell poorly, but many will not as long as demand remains within historical norms.

 

Read More

Continue Reading

Spread & Containment

Lab, crab and robotic rehab

I was in Berkeley a couple of months back, helping TechCrunch get its proverbial ducks in a row before our first big climate event (coming in a few weeks,…

Published

on

I got previews of a number of projects I hope to share with you in the newsletter soon, but one that really caught my eye was FogROS, which was just announced as part of the latest ROS (robot operating system) rollout. Beyond a punny name that is simultaneously a reference to the cloud element (fog/cloud — not to mention the fact that the new department has killer views of San Francisco and frequent visitor, Karl) and problematic French cuisine, there’s some really compelling potential here.

I’ve been thinking about the potential impact of cloud-based processing quite a bit the last several years, independent of my writing about robots. Specifically, a number of companies (Microsoft, Amazon, Google) have been betting big on cloud gaming. What do you do when you’ve seemingly pushed a piece of hardware to its limit? If you’ve got low enough latency, you can harness remote servers to do the heavy lifting. It’s something that’s been tried for at least a decade, to varying effect.

Image Credits: ROS

Latency is, of course, a major factor in gaming, where being off by a millisecond can dramatically impact the experience. I’m not fully convinced that experience is where it ought to be quite yet, but it does seem the tech has graduated to a point where off-board processing makes practical sense for robotics. You can currently play a console game on a smartphone with one of those services, so surely we can produce smaller, lighter-weight and lower-cost robots that rely on a remote server to complete resource-intensive tasks like SLAM processing.

The initial application will focus on AWS, with plans to reach additional services like Google Cloud and Microsoft Azure. Watch this space. There are many reasons to be excited. Honestly, there’s a lot to be excited about in robotics generally right now. This was one of the more fun weeks in recent memory.

V Bionic's exoskeleton glove shown without its covering.

Image Credits: V Bionic

Let’s start with the ExoHeal robotic rehabilitation gloves. The device, created by Saudi Arabian V Bionic, nabbed this year’s Microsoft Imagine Cup. The early-stage team is part of a proud tradition of healthcare exoskeletons. In this case, it’s an attempt to rehab the hand following muscle and tendon injuries. Team leader Zain Samdani told TechCrunch:

Flexor linkage-driven movement gives us the flexibility to individually actuate different parts of each finger (phalanges) whilst keeping the device portable. We’re currently developing our production-ready prototype that utilizes a modular design to fit the hand sizes of different patients.

Image Credits: Walmart

This is the third week in a row Walmart gets a mention here. First it was funding for GreyOrange, which it partnered with in Canada. Last week we noted a big expansion of the retail giant’s deal with warehouse automation firm, Symbotic. Now it’s another big expansion of an existing deal — this time dealing with the company’s delivery ambitions.

Like Walmart’s work with robotics, drone delivery success has been…spotty, at best. Still, it’s apparently ready to put its money where its mouth is on this one, with a deal that brings DroneUp delivery to 34 sites across six U.S. states. Quoting myself here:

The retailer announced an investment in the 6-year-old startup late last year, following trial deliveries of COVID-19 testing kits. Early trials were conducted in Bentonville, Arkansas. This year, Arizona, Florida, Texas and DroneUp’s native Virginia are being added to the list. Once online, customers will be able to choose from tens of thousands of products, from Tylenol to hot dog buns, between the hours of 8 a.m. and 8 p.m.

Freigegeben für die Berichterstattung über das Unternehemn Wingcopter bis zum 25.01.2026. Mit Bitte um Urhebervermerk v.l.: Jonathan Hesselbarth, Tom Plümmer und Ansgar Kadura von Wingcopter GmbH. Image Credits: © Jonas Wresch / KfW

There are still more question marks around this stuff than anything, and I’ve long contended that drone delivery makes the most sense in remote and otherwise hard to reach areas. That’s why something like this Wingcopter deal is interesting. Over the next five years, the company plans to bring 12,000 of its fixed-wing UAVs to 49 countries across Sub-Saharan Africa. It will cover spots that have traditionally struggled with infrastructural issues that have made it difficult to deliver food and medical supplies through more traditional means.

“With the looming food crisis on the African continent triggered by the war in Ukraine, we see great potential and strong social impact that drone-delivery networks can bring to people in all the countries in Sub-Saharan Africa by getting food to where it is needed most,” CEO Tom Plümmer told TechCrunch. “Especially in remote areas with weak infrastructure and those areas that are additionally affected by droughts and other plagues, Wingcopter’s delivery drones will build an air bridge and provide food from the sky on a winch to exactly where it is needed.”

Legitimately exciting stuff, that.

Image Credits: Dyson

In more cautiously optimistic news, Dyson dropped some interesting news this week, announcing that it has been (and will continue) pumping a lot of money into robotic research. Part of the rollout includes refitting an aircraft hangar at Hullavington Airfield, a former RAF station in Chippenham, Wiltshire, England that the company purchased back in 2016.

Some numbers from the company:

Dyson is halfway through the largest engineering recruitment drive in its history. Two thousand people have joined the tech company this year, of which 50% are engineers, scientists, and coders. Dyson is supercharging its robotics ambitions, recruiting 250 robotics engineers across disciplines including computer vision, machine learning, sensors and mechatronics, and expects to hire 700 more in the robotics field over the next five years. The master plan: to create the UK’s largest, most advanced, robotics center at Hullavington Airfield and to bring the technology into our homes by the end of the decade.

The primary project highlighted is a robot arm with a number of attachments, including a vacuum and a human-like robot hand, which are designed to perform various household tasks. Dyson has some experience building robots, primarily through its vacuums, which rely on things like computer vision to autonomously navigate. Still, I say “cautiously optimistic,” because I’ve seen plenty of non-robotics companies showcase the technology as more of a vanity project. But I’m more than happy to have Dyson change my mind.

Image Credits: Hyundai

Hyundai, of course, has been quite aggressive in its own robotics dreams, including its 2020 acquisition of Boston Dynamics. The carmaker this week announced that part of its massive new $10 billion investment plans will include robotics, with a focus of actually bringing some of its far-out concepts to market.

Another week, another big round for logistics/fulfillment robotics, as Polish firm Nomagic raised $22 million to expand its offerings. The company’s primary offering is a pick and place arm that can move and sort small goods. Khosla Ventures and Almaz Capital led the round, which also featured European Investment Bank, Hoxton Ventures, Capnamic Ventures, DN Capital and Manta Ray.

Amazon Astro with periscope camera

The periscope camera pops out and extends telescopically, enabling Astro to look over obstacles and on counter tops. A very elegant design choice. Image Credits: Haje Kamps for TechCrunch

We finally got around to reviewing Amazon’s limited-edition home robot, Astro, and Haje’s feelings were…mixed:

It’s been fun to have Astro wandering about my apartment for a few days, and most of the time I seemed to use it as a roving boom box that also has Alexa capabilities. That’s cute, and all, but $1,000 would buy Alexa devices for every thinkable surface in my room and leave me with enough cash left over to cover the house in cameras. I simply continue to struggle with why Astro makes sense. But then, that’s true for any product that is trying to carve out a brand new product category.

A tiny robot crab scuttles across the frame. Image Credits: Northwestern University

And finally, a tiny robot crab from Northwestern University. The little guy can be controlled remotely using lasers and is small enough to sit on the side of a penny. “Our technology enables a variety of controlled motion modalities and can walk with an average speed of half its body length per second,” says lead researcher, Yonggang Huang. “This is very challenging to achieve at such small scales for terrestrial robots.”

Image Credits: Bryce Durbin/TechCrunch

Scuttle, don’t walk to subscribe to Actuator.

Read More

Continue Reading

Trending